Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02429375 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Mocetinostat Plus Brentuximab Vedotin

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]